Publications by authors named "E Sardh"

Article Synopsis
  • Givosiran is an RNA interference drug approved to treat acute hepatic porphyria, particularly acute intermittent porphyria, and this study examined its long-term safety and efficacy over a follow-up period of up to 48 months.* -
  • Sixteen participants, aged 18-65, were monitored for adverse events, changes in specific biomarker levels, rates of porphyria attacks, and quality of life; common side effects included abdominal pain and nausea.* -
  • Results showed a significant reduction in porphyria attacks (97%) and hemin usage (96%), with all patients free from major attacks after 33 months, along with notable improvements in urinary biomarkers and quality of life.*
View Article and Find Full Text PDF

Background: We describe the case of a 47-year-old man referred to a retinal clinic and diagnosed with late-onset retinitis pigmentosa. Surprisingly, genetic testing revealed compound heterozygous pathogenic variants in GNPTG, leading to the diagnosis of the autosomal recessive lysosomal storage disorder mucolipidosis type III gamma. Mucolipidosis type III gamma is typically diagnosed during childhood due to symptoms relating to skeletal dysplasia.

View Article and Find Full Text PDF

Acute intermittent porphyria (AIP) is a rare hereditary metabolic disease characterized by acute attacks and accumulation of the porphyrin precursors 5-aminolevulinic acid (ALA) and porphobilinogen (PBG). Patients with AIP have a high risk of primary liver cancer (PLC). We aimed to assess the association between porphyrin precursor excretion and the risk for PLC in patients with AIP.

View Article and Find Full Text PDF

Current knowledge of pregnancy and perinatal outcomes in women with acute hepatic porphyria (AHP) is largely based on biochemical disease models, case reports, and case series. We performed a nationwide, registered-based cohort study to investigate the association between maternal AHP and the risk of adverse pregnancy and perinatal outcomes. All women in the Swedish Porphyria Register with confirmed AHP aged 18 years or older between 1987 and 2015 and matched general population comparators, with at least one registered delivery in the Swedish Medical Birth Register were included.

View Article and Find Full Text PDF